Technical Aspects and Clinical Impact of Hematopoietic Progenitor Subset Quantification
- 1 March 2000
- journal article
- review article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 18 (2) , 76-86
- https://doi.org/10.1634/stemcells.18-2-76
Abstract
As high-dose therapy for malignancies is now being applied to newly diagnosed patients as adjuvant therapy, it has become a requirement that quality and safety assessment of hematopoietic stem cell grafts be evidence-based. This process has developed a new institution in medicine, the stem cell laboratory. In most cases this speciality has evolved from or within hematological research laboratories. However, the increased routine technologies applied in quality evaluation, ex vivo manipulation and safety assessment in stem cell handling naturally places this activity in transfusion medicine. Multiparametric flow cytometry can identify progenitor subsets in normal human bone marrow and peripheral blood, and such subset quantification has been used retrospectively to predict three-lineage engraftment following high-dose therapy for malignancies. Published single center data have suggested an impact on clinical outcome, and a standardized technique for subset enumeration needs to be established before prospective multicenter trials can be initiated to document the prognostic value of such quality assessment in autografting. Based on experiences of CD34 enumeration, which we consider to be the first step in quality assessment of hematopoietic stem cell grafts, this review discusses flow cytometry subset identification by lineage-specific differentiation markers, stromal-dependent adherence molecules, and regulatory growth factor receptors from a technical point of view. The aim of this review is:To recommend a simple method based on the experiences of the Nordic workshop III on subset identification; To present new molecular genetic-based methods for future use in quality assessment; and To propose new endpoints necessary for validation of the likely clinical impact of subsets in prospective trials. As sample differences between blood and marrow result in technical difficulties, this review only focuses on the methodology of identifying subsets in blood and leukapheresis products. Methods for subset analysis in diagnostic bone marrow samples will be covered in a forthcoming review.Keywords
This publication has 73 references indexed in Scilit:
- CD34+/CD41a+ cells best predict platelet recovery after autologous peripheral blood stem cell transplantationBone Marrow Transplantation, 1998
- Improved Priming for Mobilization of and Optimal Timing for Harvest of Peripheral Blood Stem CellsJournal of Hematotherapy, 1996
- Long-Term Lymphohematopoietic Reconstitution by a Single CD34-Low/Negative Hematopoietic Stem CellScience, 1996
- Letter to the Editor: Standardization of Absolute CD34 Cell EnumerationJournal of Hematotherapy, 1996
- North American Multicenter Study on Flow Cytometric Enumeration of CD34+ Hematopoietic Stem CellsJournal of Hematotherapy, 1996
- Phenotypic Analysis and Characterization of CD34+ Cells from Normal Human Bone Marrow, Cord Blood, Peripheral Blood, and Mobilized Peripheral Blood from Patients Undergoing Autologous Stem Cell TransplantationClinical Immunology and Immunopathology, 1994
- Peripheral Blood Progenitor Cell Transplantation Estimated by Three-Colour (CD34, HLA-DR, CD33) Flow CytometryActa Haematologica, 1994
- Commentary: Prospects for Standardization of Stem Cell Determination within EuropeJournal of Hematotherapy, 1993
- Purified primitive human hematopoietic progenitor cells with long-term in vitro repopulating capacity adhere selectively to irradiated bone marrow stroma.The Journal of Experimental Medicine, 1990
- Human hematopoietic precursors in long-term culture: single CD34+ cells that lack detectable T cell, B cell, and myeloid cell antigens produce multiple colony-forming cells when cultured with marrow stromal cells.The Journal of Experimental Medicine, 1990